D69.49 — Other primary thrombocytopeniaICD-10-CM
No Prior Auth Required
Code is covered without prior authorization (high confidence)
A57554 — Billing and Coding: Immune Globulins
J05
A57878 — Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J05
L40277 — MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J05
A55639 — Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
J05
Ask Verity about documentation requirements, denial risks, or coverage in your state.
L34771 — Immune Globulins
J05
L38176 — MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J05
L37205 — Chemotherapy Drugs and their Adjuncts
J05
A60309 — Billing and Coding: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J05
L39297 — Off-label Use of Rituximab and Rituximab Biosimilars
J06
A56199 — Billing and Coding: Molecular Pathology Procedures
J06
L39314 — Off-Label Use of Intravenous Immune Globulin (IVIG)
J06
L37606 — Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J06
A56793 — Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J06
L35000 — Molecular Pathology Procedures
J06
A60186 — Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
J06
A60187 — Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)
J06
A59898 — Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J06
A59926 — Billing and Coding: Molecular Pathology Procedures
J06
A59101 — Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
J06
A59105 — Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)
J06